Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 10/20 | 0.36 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | PRKG2 | Q13237 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23843301 | 0.83 | NR3C2 (0.34) | TRPM8NR3C2 | |
| SCHEMBL22639199 | 0.80 | PNMT (0.36) | HTR2AHTR2CHTR2BNR3C2 | |
| SCHEMBL18763524 | 0.76 | ADRB2 (0.46) | HTR2AHTR2CHTR2BCYP3A4NR3C2 | |
| SCHEMBL4547925 | 0.75 | TRPM8 (0.47) | TRPM8CXCR4HSD11B1 | |
| SCHEMBL14519455 | 0.74 | TRPM8 (0.42) | TRPM8CXCR4HSD11B1 | |
| SCHEMBL25744955 | 0.74 | HTR2A (0.33) | HTR2AHTR2CHTR2BNR3C2 | |
| SCHEMBL19227962 | 0.72 | NR3C2 (0.56) | HTR2AHTR2CHTR2BNR3C2 | |
| SCHEMBL26061532 | 0.71 | TRPM8 (0.34) | TRPM8CXCR4 | |
| SCHEMBL12120626 | 0.70 | GABRA1 (0.40) | HTR2AHTR2CHTR2BNR3C2 | |
| SCHEMBL20694181 | 0.70 | NR3C2 (0.42) | CYP3A4NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951053-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | SAMUMED, LLC (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170260176-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | MED-PATHWAYS II LIMITED (VG) | 2017-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260176-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | GSK3A, GSK3B, WNT1 | TRPM8 2154/4885CXCR4 418/4885HTR2A 2655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.